ArticleCancer cell international2026
TMT proteomics reveals that miR-425-5p promotes proliferation and metastasis of malignant melanoma by inhibiting SCARA5.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundWhile the relationship between miRNAs and malignant melanoma is well-established, the role of miR-425-5p in melanoma remains underexplored. This study investigated the molecular mechanisms underlying miR-425-5p-mediated regulation of malignant melanoma proliferation and metastasis, with emphasis on its interaction with scavenger receptor class A member 5 (SCARA5).
methodsThe impact of SCARA5 and miR-425-5p on melanoma cell proliferation and metastatic potential was assessed using CCK-8, clonogenic, scratch, and Transwell assays. Western blotting was employed to quantify apoptosis markers, epithelial-mesenchymal transition (EMT)-related proteins, and components of the Akt signaling pathway. Bioinformatics and dual-luciferase reporter assays validated the direct interaction between miR-425-5p and SCARA5. In vivo, a subcutaneous tumor model in nude mice was used to evaluate tumor growth, and TUNEL staining was performed to assess apoptosis. Tandem Mass Tag (TMT) proteomics was applied to comprehensively identify downstream pathways modulated by miR-425-5p.
resultsSilencing SCARA5 in A375 and A2058 cells downregulated the expression of caspase-3 and E-cadherin levels while elevating Bcl-2, p-AKT, N-cadherin, β-catenin, and ZEB1 levels. Conversely, SCARA5 overexpression reversed these effects. Dual-luciferase assays confirmed that miR-425-5p could directly target SCARA5. Inhibition of miR-425-5p expression increased SCARA5 expression and suppressed proliferation/metastasis, whereas miR-425-5p mimics reduced SCARA5 expression and enhanced malignancy. In the in vivo model, SCARA5 overexpression significantly inhibited tumor growth, while the administration of miR-425-5p agonists promoted it. Proteomics further revealed that miR-425-5p could suppress the PPARγ pathway and activate the AKT signaling pathway.
conclusionOur findings demonstrate that miR-425-5p promotes melanoma progression by downregulating SCARA5, thereby inhibiting apoptosis, activating AKT phosphorylation, and inducing EMT. These findings identify the miR-425-5p/SCARA5 axis as a potential therapeutic target for melanoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.